Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion
NASDAQ:WHWK

Whitehawk Therapeutics 8/7/2025 Earnings Report

Whitehawk Therapeutics logo
$4.49 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$4.48 -0.01 (-0.22%)
As of 05/22/2026 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Whitehawk Therapeutics EPS Results

Actual EPS
-$0.76
Consensus EPS
$0.49
Beat/Miss
Missed by -$1.25
One Year Ago EPS
N/A

Whitehawk Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$100.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Whitehawk Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Whitehawk Therapeutics Earnings Headlines

$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…tc pixel
See More Whitehawk Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Whitehawk Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Whitehawk Therapeutics and other key companies, straight to your email.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

View Whitehawk Therapeutics Profile